sulfinpyrazone has been researched along with Arteriosclerosis in 42 studies
Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.
Arteriosclerosis: Thickening and loss of elasticity of the walls of ARTERIES of all sizes. There are many forms classified by the types of lesions and arteries involved, such as ATHEROSCLEROSIS with fatty lesions in the ARTERIAL INTIMA of medium and large muscular arteries.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of sulfinpyrazone on endothelial injury induced by homocysteine has been studied both in vitro, using cultured human umbilical vein endothelial cells, and in vivo, using a primate model of homocysteine-induced arteriosclerosis." | 7.66 | Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons. ( Harker, LA; Harlan, JM; Ross, R, 1983) |
| "Accelerated graft arteriosclerosis is a major cause of death in human heart transplantation." | 1.26 | Pathogenesis and prevention of graft arteriosclerosis in an experimental heart transplant model. ( Billingham, ME; Harrison, DC; Jamieson, SW; Lurie, KG; Reitz, BA, 1981) |
| "Coronary heart disease is the leading cause of death in the gouty and nongouty population." | 1.26 | Changing trends of mortality in gout. ( Talbott, JH; Yü, T, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (97.62) | 18.7374 |
| 1990's | 1 (2.38) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Loew, D | 1 |
| Breddin, K | 1 |
| Uberla, K | 1 |
| Murray, PD | 1 |
| Garnic, JD | 1 |
| Bettmann, MA | 1 |
| Faxon, DP | 1 |
| Sanborn, TA | 1 |
| Haudenschild, CC | 2 |
| Ryan, TJ | 1 |
| Packham, MA | 4 |
| Mustard, JF | 4 |
| Bousser, MG | 1 |
| Mehta, J | 2 |
| Comberg, HU | 1 |
| Janssen, EJ | 1 |
| Diehm, C | 1 |
| Zimmermann, R | 1 |
| Harenberg, J | 1 |
| Walter, E | 1 |
| Oster, P | 1 |
| Allenberg, J | 1 |
| Horsch, AK | 2 |
| Mörl, H | 1 |
| Eichner, ER | 1 |
| Cain, TD | 1 |
| Wood, JS | 1 |
| Beard, OW | 1 |
| Harker, LA | 4 |
| Harlan, JM | 1 |
| Ross, R | 1 |
| Kinlough-Rathbone, RL | 3 |
| Fuster, V | 1 |
| Chesebro, JH | 1 |
| Lurie, KG | 1 |
| Billingham, ME | 1 |
| Jamieson, SW | 1 |
| Harrison, DC | 1 |
| Reitz, BA | 1 |
| Sloan, RW | 1 |
| Mehta, JL | 1 |
| Verdecchia, P | 1 |
| Grodzińska, L | 1 |
| Dembińska-Kieć, A | 1 |
| Clopath, P | 1 |
| Dieterle, W | 1 |
| Yü, T | 1 |
| Talbott, JH | 1 |
| Paredero Del Bosque Martin, V | 1 |
| Jobin, F | 1 |
| Moore, S | 2 |
| Ihnatowycz, TO | 1 |
| Barnett, HJ | 1 |
| Verstraete, M | 1 |
| Strano, A | 1 |
| Novo, S | 1 |
| Ciammaichella, A | 1 |
| Nenci, GG | 1 |
| Agnelli, G | 1 |
| Berrettini, M | 1 |
| Parise, P | 1 |
| Ballatori, E | 1 |
| Deykin, D | 1 |
| Hirsh, J | 2 |
| Gent, M | 2 |
| Genton, E | 2 |
| Mittal, SR | 1 |
| Mathur, AK | 1 |
| Tandon, R | 1 |
| Gelman, JS | 1 |
| Frishman, WH | 1 |
| Miller, KP | 1 |
| Fujimoto, T | 1 |
| Yamazaki, H | 1 |
| Valladares, BK | 1 |
| Lemberg, L | 1 |
| Di Perri, T | 1 |
| Grunwald, J | 1 |
| Born, GV | 1 |
| Perlick, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
17 reviews available for sulfinpyrazone and Arteriosclerosis
| Article | Year |
|---|---|
Pharmacology of platelet-affecting drugs.
Topics: Animals; Arachidonic Acids; Arteriosclerosis; Aspirin; Blood Platelets; Cyclic AMP; Dose-Response Re | 1980 |
Platelets, carotids, and coronaries. Critique on antithrombotic role of antiplatelet agents, exercise, and certain diets.
Topics: Angina Pectoris; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Carotid Artery Thrombosi | 1984 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
[Platelets and prostaglandins in ischemic cardiopathy. Theoretical and practical aspects and research prospects].
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Humans; Platelet Aggrega | 1982 |
[Blood platelets and cardiovascular diseases. IV. Platelet-inhibiting drugs and antithrombotic agents].
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Analgesics; Anti-Inflammatory Agents; Arterioscl | 1976 |
Vessel injury and atherosclerosis.
Topics: Animals; Arteries; Arteriosclerosis; Blood Platelets; Cholesterol; Diet; Humans; Hypercholesterolemi | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
Platelets and thrombosis in the development of atherosclerosis and its complications.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Dipyridamole; Endothelium; Human | 1978 |
The pathophysiology of transient cerebral ischemic attacks.
Topics: Arteriosclerosis; Aspirin; Carotid Arteries; Cerebrovascular Disorders; Cholesterol; Embolism; Endoc | 1979 |
[Prophylactic value of platelet anti-aggregants in coronary disease].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Clofibrate; Coronary Disease; Dipyridamole; Embolism; Hea | 1979 |
[Prospects of antiaggregant therapy in prevention of atherosclerosis].
Topics: Animals; Anti-Inflammatory Agents; Anticoagulants; Arteriosclerosis; Aspirin; Blood Coagulation Diso | 1979 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Platelets and prostaglandins in sudden death: therapeutic implications.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acid; Arachidonic Acids; Arteriosclerosis; Aspirin | 1985 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
Antiplatelet drugs in the management of patients with thrombotic disorders.
Topics: Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Blood Coagulation Disorders; Blood Platelets | 1986 |
[Thrombosis in various diseases: arteriosclerosis and thrombosis].
Topics: Animals; Arteriosclerosis; Aspirin; Dipyridamole; Humans; Sulfinpyrazone; Thrombosis | 1986 |
Platelet pharmacology in relation to thrombosis.
Topics: Adenine Nucleotides; Animals; Arteriosclerosis; Aspirin; Binding Sites; Blood Cells; Blood Coagulati | 1970 |
8 trials available for sulfinpyrazone and Arteriosclerosis
| Article | Year |
|---|---|
[Role of antiplatelet agents in the prevention of cerebral ischemic accidents].
Topics: Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; C | 1983 |
Platelets and prostaglandins in coronary artery disease. Rationale for use of platelet-suppressive drugs.
Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials as Topic; Coronary Disease; Dip | 1983 |
[Sulfinpyrazone (Anturan) versus placebo following surgical reconstruction of the femoral artery in arterial occlusive diseases].
Topics: Adult; Aged; Arterial Occlusive Diseases; Arteriosclerosis; Clinical Trials as Topic; Double-Blind M | 1983 |
Medical Grand Rounds: extracranial carotid artery disease.
Topics: Adolescent; Adult; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Auscultation; Carotid Art | 1980 |
Series on pharmacology in practice. 10. Antithrombotic therapy: role of platelet-inhibitor drugs. III. Management of arterial thromboembolic and atherosclerotic disease (third of three parts).
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Coro | 1981 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
Platelet-inhibiting drugs in the prevention of clinical thrombotic disease (second of three parts).
Topics: Aged; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Cardiac Catheterization; Clinical Tria | 1975 |
Platelets and antiplatelet therapy in ischemic heart disease.
Topics: Angina Pectoris; Angioplasty, Balloon; Arteriosclerosis; Aspirin; Blood Platelets; Clinical Trials a | 1986 |
21 other studies available for sulfinpyrazone and Arteriosclerosis
| Article | Year |
|---|---|
[Inhibitors of thrombocytic function for prophylaxis of coronary heart disease (author's transl)].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Anticoagulants; Arteriosclerosis; Aspirin; Coronary Diseas | 1982 |
Pharmacology of angioplasty and intravascular thrombolysis.
Topics: Angioplasty, Balloon; Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Dextrans; Dipyrida | 1982 |
Effect of antiplatelet therapy on restenosis after experimental angioplasty.
Topics: Angioplasty, Balloon; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Iliac Arter | 1984 |
Effect of sulfinpyrazone on homocysteine-induced endothelial injury and arteriosclerosis in baboons.
Topics: Animals; Arteries; Arteriosclerosis; Cells, Cultured; Endothelium; Homocysteine; Humans; Male; Papio | 1983 |
Non-steroidal anti-inflammatory agents and coronary heart disease.
Topics: Animals; Anti-Inflammatory Agents; Arteriosclerosis; Aspirin; Blood Platelets; Blood Vessels; Caroti | 1980 |
Pathogenesis and prevention of graft arteriosclerosis in an experimental heart transplant model.
Topics: Animals; Arteriosclerosis; Cyclosporins; Dipyridamole; Drug Therapy, Combination; Graft Rejection; H | 1981 |
Antiplatelet therapy.
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprost | 1981 |
Platelets and coronary heart disease: therapy update.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Coronary Disease; Dipyridamole; Epoprostenol; Hemostasis | 1982 |
Sulphinpyrazone inhibits development of atherosclerosis in rabbits.
Topics: Animals; Arteriosclerosis; Diet, Atherogenic; Male; Platelet Aggregation; Rabbits; Sulfinpyrazone | 1980 |
[The effect of sulfinpyrazone on the arteriosclerotic changes in various animal models].
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Guinea Pigs; Male; Rabbits; Sulfinpyrazone; Swine | 1980 |
Changing trends of mortality in gout.
Topics: Aged; Arteriosclerosis; Coronary Disease; Female; Gout; Humans; Kidney Diseases; Male; Middle Aged; | 1980 |
[Indications for surgical treatment and medical treatment of atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Cholestyramine Resin; Clofibrate; Dextrothyroxine; Dipyridamole; Humans; | 1980 |
[Current status of vascular diseases and their treatment].
Topics: Arteriosclerosis; Aspirin; Clofibrate; Humans; Indomethacin; Sulfinpyrazone; Vasodilator Agents | 1979 |
Inhibition of spontaneous platelet aggregation by sulfinpyrazone.
Topics: Aged; Arteriosclerosis; Diabetes Mellitus; Double-Blind Method; Humans; Hyperlipidemias; Male; Middl | 1979 |
Antithrombotic therapy. Rationale and application.
Topics: Anticoagulants; Arteries; Arteriosclerosis; Aspirin; Blood Coagulation; Blood Coagulation Factors; D | 1979 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Platelets, thrombosis and atherosclerosis.
Topics: Arteries; Arteriosclerosis; Aspirin; Blood Platelets; Cell Division; Cell Survival; Dipyridamole; En | 1977 |
Human equivalent doses of platelet inhibitors and experimental atherosclerosis.
Topics: Animals; Aorta; Arteriosclerosis; Aspirin; Blood Platelets; Dipyridamole; Dose-Response Relationship | 1990 |
Platelet aggregation and atherosclerosis.
Topics: Arteriosclerosis; Aspirin; Dipyridamole; Electrocardiography; Humans; Male; Middle Aged; Myocardial | 1986 |
[Prevention and medical treatment of polyregional vascular lesions].
Topics: Adult; Anticoagulants; Arterial Occlusive Diseases; Arteriosclerosis; Aspirin; Diet; Dipyridamole; D | 1985 |
The influence of antiplatelet drugs on injury-stimulated migration of cultured smooth muscle cells.
Topics: Animals; Arteriosclerosis; Aspirin; Catheterization; Cell Movement; Cells, Cultured; Dipyridamole; H | 1985 |
[Thrombophilia in early and late sclerosis].
Topics: Age Factors; Anticoagulants; Arteries; Arteriosclerosis; Dipyridamole; Humans; Lipid Metabolism; Nuc | 1968 |